Novo Nordisk stock falls after Morgan Stanley downgrade as GLP-1 risks loom
Published on 09/13/2026 at 14:39 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Novo Nordisk stock (ISIN DK0062498333) has come under renewed pressure in mid September, with the Danish pharmaceutical group’s shares losing about 7.6 percent over the last seven trading days after a rating downgrade by Morgan Stanley around September 11, 2026.
Morgan Stanley downgrade hits sentiment
According to Trading-Treff on September 12, 2026, Morgan Stanley cut its recommendation on Novo Nordisk shares from Equal-weight to Underweight, citing a cautious medium-term growth outlook and concerns about the patent expiry of the GLP-1 drug semaglutide.
The same report notes that Morgan Stanley projects revenue and EBIT growth of only 2 to 3 percent in 2027 and around 4 percent per year between 2027 and 2030, compared with an expected 4 percent revenue and 7 percent EBIT growth for the broader European pharma sector, underscoring fears that Novo Nordisk could lag peers in profitability over time.Trading-Treff
As reported by Stock-World on September 13, 2026, Novo Nordisk’s shares in Frankfurt closed at 37.05 euros on September 11, 2026, down 2.6 percent from the previous day, and accumulated a decline of 7.6 percent over the prior seven sessions, illustrating how quickly sentiment turned after the downgrade.
GLP-1 concentration and patent risk
The downgrade hinges largely on Novo Nordisk’s heavy dependence on semaglutide, the active ingredient behind blockbuster brands such as Ozempic and Wegovy. Trading-Treff highlights that semaglutide is expected to account for about 75 percent of Novo Nordisk’s total revenue in 2026, raising questions over how the company will navigate patent expiries and intensifying competition in GLP-1 therapies.Trading-Treff
TipRanks also points to mounting concerns around the GLP-1 segment, noting in a weekend update that Novo Nordisk’s New York-listed ADR (ticker NVO) fell 7.58 percent over a recent period as GLP-1 fears gained traction among investors.TipRanks
From a risk perspective, the combination of high product concentration, impending patent expiries and strong competition from rivals such as Eli Lilly in obesity and diabetes markets makes future growth more exposed to shifts in clinical outcomes, regulatory decisions and pricing dynamics than for more diversified pharma peers.
Contrasting analyst views and buyback support
The bearish stance from Morgan Stanley is not unanimous in the analyst community. Trading-Treff reports that HSBC raised its price target for Novo Nordisk shares from 300 to 320 Danish kroner on September 9, 2026, providing a more constructive view on the company’s long-term potential.Trading-Treff
Despite the recent share price pressure, Novo Nordisk is continuing its share buyback program. According to Trading-Treff, the company repurchased around 32 million B shares up to September 4, 2026 at an average price of 281.63 Danish kroner, corresponding to a total transaction value of approximately 9.02 billion Danish kroner, underpinning the capital-return story even as the market reassesses the growth trajectory.Trading-Treff
These figures give investors a tangible sense of scale: at the reported average repurchase price, Novo Nordisk has bought back shares equivalent to more than 9 billion Danish kroner in value, a move that can support earnings per share over time but does not itself resolve the underlying product concentration risk.
Fundamentals and upcoming capital markets day
While the latest weekly sources focus on sentiment and strategic questions, Trading-Treff notes that Novo Nordisk has invited staff to a townhall meeting ahead of a capital markets day scheduled for September 21, 2026, which the market views as a key moment for management to outline how it intends to reduce its reliance on semaglutide and recapture lost GLP-1 market share.Trading-Treff
Recent reports also mention progress in Novo Nordisk’s pipeline across metabolic and liver diseases. Stock-World points out that Wegovy has received approval in China for MASH (metabolic dysfunction-associated steatohepatitis), marking another regulatory milestone for the company’s GLP-1-based therapies, even though this positive news did not prevent the share price from falling in recent sessions.Stock-World
From an investor perspective, the capital markets day on September 21, 2026 will therefore serve as an important checkpoint to see whether management can present credible diversification plans and new growth drivers that could offset the patent and competition risks currently weighing on Novo Nordisk stock.
Stock performance and technical picture
In Frankfurt, Stock-World reports that Novo Nordisk’s shares closed at 37.05 euros on September 11, 2026, representing a 2.6 percent decline from the prior close and extending the cumulative seven-day drop to 7.6 percent, with the stock trading about 32 percent below its 52-week high of 54.86 euros reached in January 2026.Stock-World
The same article notes that the shares have fallen about 16 percent on a one-year basis and roughly 20 percent over the past twelve months, highlighting that the current setback comes on top of an already negative medium-term performance profile.Stock-World
Technically, Stock-World cites a relative strength index (RSI) of 34 for Novo Nordisk shares and notes that the stock is about 7.6 percent below its 200-day moving average, both signals typically associated with an oversold condition but also indicative of a persistent downtrend that has not yet found a clear bottom.Stock-World
Closing view on Novo Nordisk stock
As of the latest available European trading data for September 11, 2026, Novo Nordisk stock remains well below its January 2026 52-week high, with a cumulative decline of 7.6 percent over seven days and about 32 percent below that peak in euro terms, reflecting how strongly the recent analyst downgrade and GLP-1 risk debate have affected sentiment.
Novo Nordisk stock at a glance
- Company: Novo Nordisk A/S
- ISIN: DK0062498333
- Ticker: NOVO-B
- Trading venue: Nasdaq Copenhagen
- Sector / Industry: Health Care / Pharmaceuticals
- Index membership: OMX Copenhagen 25
